GHENT, Belgium -Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease. This is the first lead candidate emerging from the Alzheimer's disease collaboration between Ablynx and Boehringer Ingelheim, and will result in a €2 million milestone payment to Ablynx. In January 2007, Boehringer Ingelheim and Ablynx announced that they had entered into a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies, worth a possible $265 million in milestone payments plus undisclosed royalties.